Pharma Mar SA · BME:PHM

Pharma Mar SA — Investor Presentation (January 2017)

28 slides from Pharma Mar SA's investor presentation, January 2017

  1. Slide 1: CNMV relevant fact notice

    Comisión Nacional del Mercado de Valores Att. Director del Área de Mercados C/Edison núm. 4 28006 Madrid Colmenar Viejo (Madrid), a 10 de enero de 2017 De conformidad con lo previsto en el artículo 228 del Texto Refundido de la Ley de Mercado de Valores, por la presente se procede a comunicar el sig

  2. Slide 2: Corporate Presentation January 2017

    CORPORATE PRESENTATION November 2016 CORPORATE PRESENTATION January 2017

  3. Slide 3: Disclaimer

    Disclaimer This document includes only summary information and is not intended to be comprehensive. This document includes "forward-looking statements" that are based on Management’s current expectations. Factors that could cause future results to differ materially from such expectations include, bu

  4. Slide 4: Investment Highlights

    Investment Highlights A leader in the development & commercialization of marine-derived oncology drugs  Multinational biotechnology company developing marine-derived and novel MoA oncology drugs  Fully integrated biotechnology company – from discovery to commercialization  Highly productive R&D o

  5. Slide 5: Yondelis - Commercial expansion worldwide

    Yondelis® - Commercial expansion worldwide PHM territories • Western EU. • Scandinavia and Eastern Europe: Swedish Orphan Biovitrum • Greece, Cyprus and Croatia: Genesis Pharma Partner territories EEUU and rest of the word (exclud. EU) :Janssen Japan : Taiho PharmaMar subsidiaries 4

  6. Slide 6: Unique fully integrated platform

    Unique fully integrated platform Fully integrated capabilities Screening Marine expeditions Sample library & Synthesis Clinical Trials Commercialization  Marine derived  New drug  Patent protection  Pre-clinical trials  Oncology-focused sales products candidates  Synthesis  Clinical trials fo

  7. Slide 7: The Plan for Growth

    The Plan for Growth Potential to commercialize new oncology products in more indications PharmaMar in the near future PharmaMar • 3 marketed tomorrow products PharmaMar • 2 marketed • ≥ 5 indications today products • 3 indications  Lurbinectedin • 1 marketed product (PM1183) • 2 indications  Aplid

  8. Slide 8: A Balanced portfolio of product candidates

    A Balanced portfolio of product candidates Overview Clinical Program / Indication Phase I Phase II Phase III Market Partner Data timing Yondelis® J&J (US) Soft Tissue Sarcoma 2nd/3rd line Single agent EU, US, Japan Taiho (Japan) Ovarian Cancer 2nd/3rd line Yondelis®+Doxil EU/Others Aplidin® Chugai/

  9. Slide 9: Pipeline – Lurbinectedin (PM1183)

    Pipeline – Lurbinectedin (PM1183) Targeted transcription Inhibitor as a cancer therapeutic  Cancer cells aberrantly deregulate specific gene expression programs with critical functions in cell differentiation, proliferation and survival (Hoadley et al 2014)  These altered gene programs in cancer c

  10. Slide 10: Lurbinectedin (PM1183): Key oncology compound – accelerating growth

    Lurbinectedin (PM1183): Key oncology compound – accelerating growth Lurbinectedin, a second generation Yondelis®, with improved PK and other attributes YONDELIS® Lurbinectedin HO MeO OCH3 IMPROVED PK PROFILE NH MeO O HO NH OCH3 N H AcO S O HO O H AcO S N O H N N O N O O OH O OH  Lurbinectedin is ad

  11. Slide 11: Pipeline – Lurbinectedin (PM1183) mechanism

    Pipeline – Lurbinectedin (PM1183) Key oncology compound – accelerating growth • Inhibition of trans-activated transcription but not of basal transcription. • Induction of the degradation of RNA Pol II but not of RNA Pol I or III. RNA POL II INHIBITION RNA POL II DEGRADATION P CDK7 P CDK9 RNAPII P P

  12. Slide 12: Lurbinectedin development strategy

    Pipeline – Lurbinectedin (PM1183) Development strategy CLINICAL PROGRAM/ INDICATION PHASE I PHASE II PHASE III MARKET PARTNERS Lurbinectedin PM1183® Chugai (Japan) Plat. Resistant ovarian cancer Single agent 2nd/3rd line SCLC Combo Doxorubicin 2nd line BRCA2 Breast cancer* Single agent 2nd/3rd line

  13. Slide 13: Lurbinectedin – Platinum Resistant Ovarian Cancer

    Lurbinectedin – Platinum Resistant Ovarian Cancer Market overview: Orphan Indication US/EU  ~ 250,000 WW new cases of ovarian cancer  ~ 150,000 WW deaths from ovarian cancer  Platinum resistant patients account for ~15% of all ovarian cancer patients  80% relapse after first line treatment with

  14. Slide 14: Standard of care for Ovarian Cancer

    Standard of care for Ovarian Cancer (per labels) Lurbinectedin: Competitive Landscape  PARP inhibitors work by blocking the action of poly (ADP-ribose) polymerase, a DNA repair enzyme; they are used after DNA damaging drugs which are highlighted below Front Line Second line 3L and beyond Sensitive

  15. Slide 15: Phase II Platinum Resistant Ovarian Cancer

    Lurbinectedin:Phase II Platinum Resistant Ovarian Cancer Trial results 1.0 PM01183 (N=17 C=4) 0.9 Topotecan (N=16 C=2) PFS Cumulative probability 0.8 Censored 0.7 5.7 mo. HR: 0.30 (95%CI 0.12-0.72) 0.6 0.5 p=0.005*  Superior PFS 0.4 1.7 mo. 0.3 0.2 0.1 0.0 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 1

  16. Slide 16: Phase III Platinum Resistant Ovarian Cancer: CORAIL

    Lurbinectedin:Phase III Platinum Resistant Ovarian Cancer CORAIL Trial Design Phase III 443 Patients Randomization 1:1 Stratified by:  ECOG PS (0 vs. ≥1  PFI (1-3 vs. > 3mths)  Prior CT (1-2 vs. 3 lines) Arm B: Arm A: PLD Lurbinectedin (D1 q4wk i.v.) (D1 q3wk i.v.) No Crossover or 3.2mg/m² Topote

  17. Slide 17: Lurbinectedin: Small Cell Lung Cancer (SCLC)

    Lurbinectedin: Small Cell Lung Cancer (SCLC) Market overview. Orphan Indication US/EU In the US per annum: In EU-28 per annum:  ~ 33,200 new cases of small cell lung cancer  ~ 46,645 new cases of small cell lung cancer  ~ 24,040 deaths from small cell lung cancer  ~ 40,700 deaths from small cell

  18. Slide 18: Standard of care for Small Cell Lung Cancer

    Standard of care for Small Cell Lung Cancer Lurbinectedin: Competitive Landscape  First line treatment. Platinum/Etoposide 2nd line 3rd line N ORR (%) Notes Lurbinectedin/Doxo 21 67 ASCO 2015 Paclitaxel Literature 29 Nature Reviews Glisson, 2011 Topo Literature 24 Glisson, 2011 CAV Literature 19 Gl

  19. Slide 19: Phase I/II Small Cell Lung Cancer

    Lurbinectedin: Phase I/II Small Cell Lung Cancer Trial results – Active treatment as second-line therapy with Doxorubicin Best RECIST v.1.1 overall response during treatment (n=21) Kaplan-Meier global PFS and according to CTFI (n=21) ORR: 67 % 1.0 (95%CI: 43-85) 0.9 0.8 Cumulative probability CR 0.7

  20. Slide 20: Phase III 2nd line SCLC: ATLANTIS

    Lurbinectedin: Phase III 2nd line Small Cell Lung Cancer ATLANTIS Trial Design SCLC (Trial initiated August 2016) • Primary endpoint: median PFS ─ HR≤ 0.7 in PFS with 90% power; ─ Futility analysis planned at n=150 events approximately • Key secondary endpoints: ─ OS • Registration Strategy − Trial

  21. Slide 21: Phase IIb in BRCA 1/2 Breast Cancer

    Lurbinectedin: Phase llb in BRCA 1/2- Breast Cancer Clinical efficacy: Progression Free Survival (PFS) and Overall Survival OS Median PFS BRCA 1/2: Median OS BRCA 1/2: 4.1 months 95% CI (2.8-5.9) 20.0 months 95% CI (10.9-31.8) BRCA 1: 2.7 95% CI (2.1-4.6) BRCA 1: 11.8 95% CI (6.5-20.0) BRCA 2: 5.9 9

  22. Slide 22: Phase IIb BRCA 1/2 Breast Cancer: ORR in subpopulations

    Lurbinectedin – Phase llb in BRCA 1/2- Breast Cancer Best ORR in specific subpopulations Prior Hormone Prior Platinum BRCA advanced Status CT lines Triple No Yes 1 2 1/2 HR+ 0-1 2-3 Negative (n: 27) (n: 27) (n: 31) (n: 23) (n: 54) (n: 21*) (n: 31) (n: 23) (n: 33) ORR 56% 26% 26% 61% 40.7% 36% 48% 52

  23. Slide 23: Registrational trial BRCA 2 Breast Cancer

    Lurbinectedin: Registrational trial BRCA 2- Breast Cancer Subject to finalization and changes In the US per annum: In the EU-28 per annum:  ~ 10,300 new cases of BRCA 2- Breast cancer  ~ 14,500 new cases of BRCA 2- Breast cancer Lurbinectedin single arm  Primary endpoint : ORR HR+, HER2-, BRCA2 m

  24. Slide 24: Pipeline - Aplidin

    Pipeline - Aplidin® First in class drug with a novel mechanism of action Aplidium albicans PLITIDEPSIN MECHANISM OF ACTION  Targets eEF1A2  Proto-oncogene over-expressed in different tumor types e.g. multiple myeloma eEF1A2  Non-canonical functions of eEF1A2:  Regulation of oxidative stress (e.g

  25. Slide 25: Pipeline – Aplidin

    Pipeline – Aplidin® First in class drug with a novel mechanism of action CLINICAL PROGRAM/ REGISTRATION INDICATION PHASE I PHASE II PHASE III APPLICATION MARKET PARTNERS Aplidin® R/R multiple myeloma 4th line; Aplidin® + Dexameth EU/others R/R T-cell lymphoma Single agent (Pivotal) R/R multiple myel

  26. Slide 26: Aplidin - ADMYRE Trial

    Aplidin® - ADMYRE Trial Phase III in Relapsed / Refractory Multiple Myeloma Phase III MM 250 Patients After 3, but no more than 6 lines of chemotherapy Randomization 2:1 Arm A: Arm B: Aplidin® + Dexamethasone Dexamethasone only (n=167) (n=83) Primary Endpoint Achieved: PFS, HR=0.65 (p=0.0054) Dossie

  27. Slide 27: Key Events

    Key Events Transformative times for Pharma Mar; catalyst rich 2017  Yondelis® approved in Japan for STS (9/2015); approved in the US for STS (10/2015)  Lurbinectedin Phase III pivotal trial initiated for SCLC (Aug. 2016)  Lurbinectedin interim activity analysis Phase III in platinum-resistant ova

  28. Slide 28: For more information: www.pharmamar.com

    For more information: www.pharmamar.com

Pharma Mar — Investor Presentation (January 2017) on 6ix